Rockville-based MacroGenics Inc. plans to sell 2.5 million shares in a secondary offering, the bulk of which would go toward advancing the biotech's oncology drug candidates through the clinic and expanding its manufacturing capacity.
Much like in MacroGenics' October initial public offering, the chief purpose of this offering is to fund the pipeline, with 1.5 million shares offered by the company and another 1 million shares coming from selling shareholders.